Alnylam Grants Ambion License to Fundamental RNAi Patents for Applications in the Research Products Market
Alnylam Pharmaceuticals, Inc. announced that it has granted Ambion, Inc. a non-exclusive license to provide research products and services in RNA interference (RNAi) under the Kreutzer-Limmer patent family owned by Alnylam. This patent family covers short interfering RNAs (siRNAs) and their use to mediate RNAi in mammalian cells.
"This agreement with Ambion reflects the value and strength of the intellectual property portfolio owned by Alnylam," said Vincent Miles, Ph.D., Senior Vice President, Business Development of Alnylam Pharmaceuticals. "With this agreement, Ambion, a recognized leader in the growing field of RNAi research products and services, becomes the fifth research products supplier, and the tenth company overall, to take a license for therapeutic or research product applications under fundamental intellectual property owned by Alnylam in the RNAi field."
"Ambion is committed to leadership in RNA-based life sciences research, particularly in RNAi," said Matt Winkler, CEO and CSO of Ambion. "Licensing the Kreutzer-Limmer patent family from Alnylam further enables Ambion to confidently provide the scientific research community with the tools it needs in this field."
Other news from the department business & finance
